958863-37-1 Usage
Uses
Used in Pharmaceutical Research:
2-(diethoxymethyl)-5,6-difluoro-1-methyl-1H-benzo[d]imidazole is used as a building block for the synthesis of new chemical compounds with diverse biological activities. Its unique structure and functional groups make it a promising candidate for the development of novel therapeutic agents.
Used in Antiviral Applications:
As a benzoimidazole derivative, 2-(diethoxymethyl)-5,6-difluoro-1-methyl-1H-benzo[d]imidazole may exhibit antiviral properties, making it a potential candidate for the development of new antiviral drugs.
Used in Antifungal Applications:
2-(diethoxymethyl)-5,6-difluoro-1-methyl-1H-benzo[d]imidazole may also possess antifungal activities, which can be utilized in the development of new antifungal agents to combat fungal infections.
Used in Anticancer Applications:
Due to the pharmacological properties of benzoimidazole derivatives, 2-(diethoxymethyl)-5,6-difluoro-1-methyl-1H-benzo[d]imidazole may have potential applications in the development of anticancer drugs, targeting various types of cancer.
Used in Drug Synthesis:
2-(diethoxymethyl)-5,6-difluoro-1-methyl-1H-benzo[d]imidazole can be used as a key intermediate in the synthesis of other pharmaceutical compounds, contributing to the development of new drugs with improved efficacy and safety profiles.
Check Digit Verification of cas no
The CAS Registry Mumber 958863-37-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,5,8,8,6 and 3 respectively; the second part has 2 digits, 3 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 958863-37:
(8*9)+(7*5)+(6*8)+(5*8)+(4*6)+(3*3)+(2*3)+(1*7)=241
241 % 10 = 1
So 958863-37-1 is a valid CAS Registry Number.
958863-37-1Relevant articles and documents
BENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR
-
Page/Page column 56, (2010/11/30)
Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
BENZIMIDAZOLYL COMPOUNDS
-
, (2010/11/29)
Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of formula (I) or pharmaceutically acceptable salts thereof, wherein Y1, R17, R2, R4, R5, R6, R7, R8, X2 and n are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
